ACELLA PHARMACEUTICALS, LLC – Trademark Portfolio
Entity Type: 16
ACELLA PHARMACEUTICALS, LLC holds 48 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 47 filings in this category. The portfolio also extends into Class 35 (Advertising & Business) across 2 Nice Classification classes. Currently, 16 trademarks are registered. Notable registered marks include ACELLA, LOUTREX, PRENATE, NICOMIDE, and NP THYROID. The owner is based in ALPHARETTA, GA.
9005 WESTSIDE PARKWAY
ALPHARETTA, GA 30009
Showing of trademarks Trademarks
Trademark Classifications
ACELLA PHARMACEUTICALS, LLC's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Advertising; business management; business administration; office functions
Frequently Asked Questions
How many trademarks does ACELLA PHARMACEUTICALS, LLC have?
ACELLA PHARMACEUTICALS, LLC has 48 U.S. trademarks filed with the USPTO. Of these, 16 registered, 23 abandoned, 9 cancelled.
What trademark classes does ACELLA PHARMACEUTICALS, LLC file in?
ACELLA PHARMACEUTICALS, LLC files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 35 (Advertising & Business). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are ACELLA PHARMACEUTICALS, LLC's most well-known trademarks?
ACELLA PHARMACEUTICALS, LLC's registered trademark portfolio includes well-known marks such as ACELLA, LOUTREX, PRENATE, NICOMIDE, and NP THYROID. These are among 16 currently registered trademarks in the portfolio.
What is ACELLA PHARMACEUTICALS, LLC's trademark registration success rate?
ACELLA PHARMACEUTICALS, LLC has a 33% trademark registration rate, with 16 out of 48 resolved applications resulting in successful registration. Currently, 0 applications are pending review.